The Gemini Brief – Investment Deep Dives

Croda International PLC (CRDA.LSE): An In-Depth Investment Analysis – Navigating Cyclical Headwinds Towards a High-Value Future

All investment deep dives on this site have been written by Google Gemini with light human editing. Nothing on this site constitutes investment advise. All materials on this site are for informational purposes only.

The Gemini Brief - Investment Deep Dives
The Gemini Brief – Investment Deep Dives
Croda International PLC (CRDA.LSE): An In-Depth Investment Analysis – Navigating Cyclical Headwinds Towards a High-Value Future
Loading
/

I. Executive Summary

This report provides a comprehensive investment analysis of Croda International PLC (“Croda” or “the Company”), a UK-based specialty chemicals company. The analysis frames Croda as a high-quality, innovation-driven leader currently navigating a significant cyclical downturn that has impacted the global chemical industry. The assessment is based on a 3-5 year investment horizon and does not provide a formal investment recommendation or price target.

The core investment thesis for Croda is centered on its resilient business model, strategic realignment towards higher-growth markets, and a valuation that has materially corrected from historical peaks. Key bullish factors include the defensibility of its high-value, low-inclusion ingredient strategy, which fosters deep customer integration and pricing power. The company’s deliberate pivot away from more cyclical industrial applications towards the knowledge-intensive niches of Life Sciences (particularly biologics drug delivery) and Consumer Care (sustainable and premium ingredients) positions it to capitalize on durable, long-term megatrends. Croda’s robust innovation pipeline, evidenced by the growing contribution from New and Protected Products (NPP), and its leadership in biotechnology and sustainable chemistry, represent significant long-term growth drivers.

Conversely, the period from 2022 to 2024 has highlighted significant risks and vulnerabilities. The severity of the industry-wide destocking cycle and macroeconomic weakness led to a sharp decline in sales volumes and profitability, exposing the negative operational leverage inherent in its integrated, shared manufacturing asset base. This has raised questions about the near-term earnings trajectory and the pace at which its historically strong profit margins can be restored. Uncertainty persists regarding the recovery timeline in key end-markets, particularly in the global crop protection sector.

The central question for investors is whether the recent downturn represents a temporary, cyclical headwind, offering an attractive entry point into a high-quality compounder, or if it signals a more structural shift in the company’s growth and margin profile. Management has responded to the challenges with a clear five-point plan focused on driving sales volumes, stepping up innovation, delivering returns from recent investments, and realigning its cost base through a multi-year efficiency program.

The long-term outlook appears favorable, contingent on management’s successful execution of these strategic priorities. Key signposts for investors to monitor will be the sustained recovery of volumes and margins in the Life Sciences segment, the continued growth of high-margin NPP sales, and the tangible delivery of targeted cost savings. The analysis concludes that while near-term uncertainty remains, Croda’s strategic positioning and fundamental business strengths provide a solid foundation for it to recapture its premium growth and margin profile over the medium term.

II. Company Overview & Business Model

Croda International PLC is a global leader in the development and manufacture of high-performance specialty chemicals. Founded in 1925, the company has evolved from its origins in lanolin production into a FTSE 100 constituent that creates ingredients essential to a wide range of consumer and industrial products.1 The company’s purpose, “Smart science to improve lives™,” underpins its strategy of leveraging scientific innovation to address global challenges in sustainability, health, and well-being.1

Core Business Segments Analysis

Following the significant divestment of a majority of its Performance Technologies and Industrial Chemicals (PTIC) businesses to Cargill in mid-2022, Croda has sharpened its focus on two primary, high-growth sectors, complemented by a smaller, retained industrial business.4

  • Consumer Care: This is Croda’s largest segment, generating sales of £920.0 million in 2024, a 7% increase at constant currency.7 The segment serves global consumer brands with innovative and sustainable ingredients across four business units: Beauty Actives, Beauty Care, Home Care, and Fragrances & Flavours (F&F).4 The F&F business, significantly enhanced by the 2020 acquisition of Iberchem, has been a standout performer, with sales growing 18% in 2024, driven by its strong position with fast-growing local and regional customers.7 The broader segment is benefiting from a recovery in volumes and a strategic focus on serving the needs of nimble, innovative local brands that are gaining market share from larger multinational corporations (MNCs).4
  • Life Sciences: This segment, with 2024 sales of £504.3 million (a 14% decline at constant currency), is strategically positioned in high-growth, high-barrier-to-entry markets.7 It comprises two main businesses:
    Pharma, which develops high-purity excipients and advanced drug delivery systems for biologics (including lipids for mRNA applications), and Agriculture, which provides formulation aids for crop protection and advanced seed enhancement technologies.8 The segment’s recent performance has been heavily impacted by the absence of £48 million in prior-year COVID-19 lipid sales and a severe, industry-wide destocking cycle in the Crop Protection market.7 However, excluding the COVID-19 sales, the segment returned to growth in the second half of 2024, and the underlying demand in biopharma applications remains a key long-term growth driver.7
  • Industrial Specialties: This is the smallest segment following the 2022 divestment, with 2024 sales of £203.8 million, up 2% at constant currency.7 The business supplies essential formulation ingredients and sustainable solutions to niche industrial markets such as coatings, water treatment, and textiles, often leveraging byproducts and co-streams from the manufacturing processes of the other two core segments.6

High-Value Ingredient Strategy

Croda’s business model is fundamentally built on a strategy of supplying “mission-critical, novel ingredients that represent a fraction of customers’ costs but are vital to the performance of their products”.3 These ingredients are typically used in low concentrations but provide essential functionality—such as emulsification, delivery of an active ingredient, or UV protection—that defines the efficacy and consumer appeal of the final product.

This “high-value, low-inclusion” model creates a powerful competitive advantage. Because the cost of Croda’s ingredient is often a negligible part of the customer’s total formulation cost, customers are less price-sensitive and more focused on performance, quality, and reliability. This dynamic allows Croda to command premium pricing and fosters deep, collaborative relationships, as its scientists often work directly with customers to solve complex formulation challenges. This customer intimacy provides valuable market insight and makes Croda an integral part of its customers’ innovation process, creating high switching costs and a durable competitive moat.

Revenue Mix & Geographic Footprint

Croda operates a global business across 39 countries, enabling it to serve both MNCs and a growing base of local and regional customers.1 In 2019, prior to recent portfolio changes, sales were distributed with Europe, Middle East & Africa (EMEA) representing the largest region, followed by North America, Asia, and Latin America.12 Recent performance highlights the increasing importance of emerging markets. In 2024, Asia was a key growth driver, with sales to the region in the Beauty Actives business increasing by 16%.9 The F&F business has a particularly strong emerging market focus, with approximately 80% of its sales in these regions.4 This geographic diversification provides resilience and access to faster-growing consumer markets.

A notable strategic shift is the increasing focus on Local & Regional (L&R) customers. These smaller, more agile brands are gaining market share globally; in the beauty and personal care market, their value share grew from 26.9% in 2018 to 30.4% in 2024.4 Croda’s business model, with its local sales teams, R&D labs, and manufacturing presence, is exceptionally well-suited to serve this customer segment. This focus is yielding tangible results: Consumer Care sales to L&R customers grew 11% at constant currency in the first half of 2025, while conditions for larger MNCs remained more challenging.10 This pivot is not merely a sales trend but a core strategic initiative that enhances the resilience of the business model by diversifying the customer base and aligning it with the most dynamic and innovative part of the market.

III. Industry Dynamics & Market Position

Croda operates within the global specialty chemicals industry, a sector characterized by innovation, application-specific products, and close customer relationships. The industry’s performance is tied to global industrial production and consumer spending but is generally less cyclical than the commodity chemicals sector due to the differentiated, high-value nature of its products.

Global Specialty Chemicals Outlook

The long-term outlook for the specialty chemicals market is positive, with various market research reports projecting a compound annual growth rate (CAGR) in the range of 4% to 5% through to 2030.14 This growth is underpinned by several key drivers:

  • Rising Demand from End-Use Industries: Growing global demand in sectors such as pharmaceuticals, personal care, electronics, and construction fuels the need for high-performance ingredients.15
  • Shift to Sustainability: A powerful, accelerating trend is the demand for “green” and sustainable chemicals. This includes bio-based feedstocks, biodegradable products, and ingredients that enable a circular economy. This shift is driven by both consumer preference and tightening environmental regulations.15
  • Technological Advancement: Innovations in fields like biotechnology, nanotechnology, and digitalization are enabling the development of novel materials and more efficient manufacturing processes, creating new growth opportunities.18
  • Growth in Emerging Economies: Rapid industrialization and rising disposable incomes in regions like Asia-Pacific are creating significant demand for specialty chemicals, with the region now accounting for the largest market share.14

The industry is currently emerging from a period of significant volatility. The post-pandemic period saw unprecedented supply chain disruptions and raw material cost inflation, followed by a widespread and severe customer destocking cycle in 2023 as macroeconomic conditions weakened.18 While the destocking phase appears to be waning, the pace of demand recovery remains a key variable for the industry in the near term.

Competitive Positioning & Moats

Croda has carved out a strong competitive position by focusing on high-value niches where it can differentiate through technology and service. Its primary competitive moats include:

  • Innovation and R&D Capabilities: With over 450 scientists, Croda’s R&D engine is its core strength.24 The company’s ability to create novel, patent-protected ingredients allows it to create and dominate new market niches. The high percentage of sales from New and Protected Products (35% in 2024) is a key indicator of its innovation leadership.7
  • Customer Intimacy and Technical Support: Croda’s direct-selling model and global network of innovation centers foster deep, collaborative relationships with customers.25 This integration into the customer’s R&D process creates high switching costs and provides invaluable market intelligence.
  • Regulatory Expertise: Operating in highly regulated markets like pharmaceuticals and crop protection requires sophisticated regulatory know-how. This expertise acts as a significant barrier to entry for potential competitors.
  • Sustainability Leadership: Croda’s long-standing focus on using renewable, bio-based raw materials is evolving from a reputational asset into a tangible commercial advantage. The company’s strategy explicitly links “Sustainability + Innovation = Growth”.11 As regulations tighten (e.g., the EU’s ban on microplastics in agriculture) and customers demand ingredients with a lower carbon footprint, Croda’s established portfolio of sustainable solutions, such as its 100% bio-based ECO surfactant range, positions it to win market share.8 This proactive stance on sustainability allows Croda to get ahead of regulatory curves that can disrupt competitors, turning compliance into a source of competitive differentiation. The company’s strong reputation is underscored by its recognition as ‘Britain’s Most Admired Chemicals Company’ for eight consecutive years.2

Peer Group Analysis

Croda’s primary competitors are other large, diversified specialty chemical companies that have a presence in personal care, pharmaceutical, and agricultural ingredients. Key peers include:

  • DSM-Firmenich AG: Formed by the 2023 merger of Dutch nutrition company DSM and Swiss fragrance house Firmenich, this entity is a global powerhouse in nutrition, health, and beauty.28 With significant scale in fragrances, flavors, and personal care ingredients, DSM-Firmenich is a direct and formidable competitor to Croda’s Consumer Care and Life Sciences segments.29
  • Evonik Industries AG: A German specialty chemicals company with a broad portfolio, including divisions that compete with Croda in areas like cosmetic ingredients and drug delivery systems.29
  • BASF SE (Care Chemicals Division): As one of the world’s largest chemical producers, BASF’s Care Chemicals division is a major player in ingredients for personal care, home care, and industrial cleaning, competing directly with Croda’s Consumer Care segment.29

While these competitors are significantly larger than Croda in terms of overall revenue, Croda’s focused strategy allows it to achieve superior profitability in its chosen niches. For instance, Croda’s historical adjusted operating margins have often been in the mid-20% range, typically higher than those of its more diversified peers, reflecting the premium nature of its portfolio.33

IV. Financial Performance & Health (5-Year Analysis: 2020-2024)

Croda’s financial performance over the past five years tells a story of a cyclical peak followed by a sharp downturn and the beginnings of a recovery. The period encapsulates the volatility of the post-pandemic era, from unprecedented demand and supply chain disruption to a widespread inventory correction. Analysis of this period is critical to understanding the company’s underlying resilience and future earnings potential.

Revenue, Profitability, and Margin Trajectory

As shown in Table 1, Croda’s revenue and profitability surged in 2021 and 2022. Sales grew from £1.39 billion in 2020 to a peak of £2.09 billion in 2022.36 This was driven by a combination of strong underlying volume growth as economies reopened, successful price increases to offset significant raw material inflation, and contributions from acquisitions, notably Iberchem and Avanti. A significant, high-margin contributor during this period was the sale of lipid systems for COVID-19 vaccines.34

The trend reversed sharply in 2023, with revenue falling to £1.69 billion as customers across key end-markets aggressively destocked inventories and macroeconomic conditions weakened.36 Adjusted profit before tax (PBT) fell even more steeply, from a peak of £496.1 million in 2022 to £308.8 million in 2023, highlighting the impact of negative operating leverage.36

In 2024, the business began to stabilize. While reported revenue declined slightly to £1.63 billion, this was primarily due to the absence of prior-year COVID-19 lipid sales and negative currency effects. Excluding these factors, sales grew 2%, driven by a recovery in volumes.7 Adjusted PBT for 2024 was £260.0 million, in line with management’s guidance.7

The company’s adjusted operating margin followed this trajectory, reaching a robust 24.7% in 2022 before contracting to 18.9% in 2023 and 17.2% in 2024.7 The decline was attributable to the under-utilization of manufacturing assets, an adverse product mix as the lower-margin F&F business grew fastest, and the loss of the high-margin COVID-19 lipid sales.10 Encouragingly, the margin showed sequential improvement in the second half of 2024, rising to 17.7% from 16.6% in the first half, reflecting higher volumes and cost control measures.7

Table 1: 5-Year Financial Summary (2020-2024)

Metric20202021202220232024
Revenue (£m)1,390.31,889.62,089.31,694.51,628.1
Adjusted Operating Profit (£m)319.6468.6515.1320.0279.7
Adjusted Profit Before Tax (PBT) (£m)300.6445.2496.1308.8260.0
Adjusted Operating Margin (%)23.0%24.8%24.7%18.9%17.2%
Adjusted Basic EPS (p)175.5250.0272.0167.6142.6
Net Debt (£m)800.0+Not Available295.2537.6532.3
Free Cash Flow (£m)176.9Not Available157.4165.5181.1
Return on Invested Capital (ROIC) (%)14.6%Not Available14.1%8.3%7.1%
Sources: Croda Annual Reports 2020, 2022, 2023, 2024; Full Year Results 2024. Data for 2021 and ROIC for 2024 is from various reports and may not be directly comparable. 7Note: Net Debt and FCF for 2021 were not readily available in the provided summary documents. ROIC for 2024 is from the Annual Report summary. 8

Segment Performance

As detailed in Table 2, the recent downturn was not uniform across Croda’s segments. The Life Sciences division experienced the most significant volatility, with adjusted operating profit falling from £229.4 million in 2022 to £150.3 million in 2023, and its margin contracting from 33.6% to 25.0% due to the crop protection destocking and lower COVID-related sales.36 The Consumer Care segment showed more resilience at the sales line but also saw its margin compress significantly, from 22.8% in 2022 to 18.1% in 2023, partly due to the under-utilization of shared manufacturing assets impacted by the Life Sciences slowdown.36 In 2024, Consumer Care led the recovery with 7% constant currency sales growth, while Life Sciences began to stabilize in the second half.7

Table 2: Segment Performance Analysis (2022-2024)

Metric202220232024
Consumer Care
Revenue (£m)897.8886.1920.0
Adjusted Operating Profit (£m)204.7160.3160.2
Adjusted Operating Margin (%)22.8%18.1%17.4%
Life Sciences
Revenue (£m)682.3602.3504.3
Adjusted Operating Profit (£m)229.4150.3104.0
Adjusted Operating Margin (%)33.6%25.0%20.6%
Industrial Specialties
Revenue (£m)509.2206.1203.8
Adjusted Operating Profit (£m)81.09.415.5
Adjusted Operating Margin (%)15.9%4.6%7.6%
Sources: Croda Annual Reports 2022, 2023; Full Year Results 2024. 8

Capital Efficiency and Returns

Return on Invested Capital (ROIC) is a key measure of management’s effectiveness in allocating capital. Croda’s ROIC has historically been strong, but it declined significantly from 14.1% in 2022 to 8.3% in 2023 and further to 7.1% in 2024.8 This reduction was a direct result of lower operating profits combined with a growing capital base following several years of heightened investment in new capacity and acquisitions. A core strategic priority for management is to improve this metric as these new investments mature and contribute to earnings growth.7

Balance Sheet Strength & Cash Flow Analysis

Croda maintains a strong and resilient balance sheet. Net debt stood at £532.3 million at the end of 2024.7 The company’s leverage ratio (net debt to EBITDA) has remained well within its target range of 1-2x, recorded at 1.3x at year-end 2023 and 1.5x at the half-year mark in 2025.13 This financial strength provides the flexibility to continue investing in strategic growth initiatives and maintain its progressive dividend policy even during downturns.

Free cash flow generation has been a notable strength. Despite the sharp fall in profits, free cash flow improved from £157.4 million in 2022 to £165.5 million in 2023, and again to £181.1 million in 2024.7 This resilience was driven by disciplined working capital management, particularly a significant reduction in inventory levels, and a moderation in capital expenditure after a period of peak investment.37

V. Navigating Recent Headwinds (2022-2024)

The period from mid-2022 through 2024 was one of the most challenging in Croda’s recent history. The company faced a confluence of external headwinds that severely tested its business model and management team. Understanding these challenges and the company’s response is crucial to assessing its future prospects.

The Great Destocking

The primary challenge was a deep and prolonged inventory correction across multiple end-markets. Following the supply chain chaos of the pandemic, many of Croda’s customers built up significant safety stocks of raw materials in 2021 and early 2022 to ensure production continuity.35 As macroeconomic conditions weakened in late 2022 and 2023, and supply chains normalized, these customers aggressively reduced their inventory levels.

This destocking was particularly acute in the Crop Protection market, where sales volumes fell sharply, and in parts of the Consumer Care business, especially in North America.27 Management described the environment in the third quarter of 2023 as weaker than anticipated, with continued inventory reduction depressing sales volumes across Consumer Care, Crop, and Industrial markets.27 During this period, management noted that order visibility was extremely low, at around two weeks, making it difficult to predict the timing of a recovery.27

Raw Material & Cost Inflation

The period was also marked by unprecedented cost inflation. Croda’s raw material basket increased by 17% in 2021 and a further 23% in 2022.35 The company demonstrated strong pricing power, successfully passing these costs on to customers through price increases, which significantly boosted the top line in 2022. However, as raw material prices began to fall in 2023 and 2024, this dynamic reversed. Price/mix became a 5.5% headwind to sales in 2024 as the company selectively passed some of these cost reductions back to customers to support volume recovery efforts.10 Beyond raw materials, the company also faced inflationary pressures in energy and labor costs.35

Geopolitical and Macroeconomic Factors

The broader operating environment was complicated by several external shocks. The conflict in Ukraine contributed to the European energy crisis, impacting operating costs.5 In China, the government’s strict zero-COVID policy and its subsequent, uneven reopening created volatility in demand patterns, although Croda still achieved modest growth in the country during 2022 despite lockdowns.35 The overall slowdown in global economic growth and rising interest rates also weighed on consumer and industrial demand.

Management’s Strategic Response

In response to these headwinds, management implemented a series of actions to protect profitability and position the company for recovery. Immediate measures included tight control over discretionary spending and headcount, which resulted in employee costs remaining broadly flat in 2023.37 The company also benefited from falling freight and energy costs.

More strategically, the downturn prompted a deeper review of the company’s cost base and operational efficiency. This has culminated in an enhanced cost-saving program. Initially targeting £40 million over two years, the program was expanded in mid-2025, with management identifying a further £60 million in savings, bringing the total annualized target to £100 million by the end of 2027.13 These savings are expected to come from efficiencies in production, procurement, and enabling functions. This proactive cost management helped to mitigate some of the margin pressure and supported the sequential margin improvement seen in the second half of 2024.7

The challenging period also exposed a key structural vulnerability in Croda’s operating model: the financial impact of under-utilization at its shared manufacturing sites. The significant drop in profit relative to sales in 2023 pointed to high negative operating leverage. Management explicitly acknowledged that the margin decline in Consumer Care was exacerbated by the need to absorb fixed costs from shared assets that were under-utilized due to the sharp volume drop in Life Sciences (Crop Protection) and Industrial Specialties.36 This operational interconnectedness means that a full recovery of group-level profit margins is not solely dependent on a rebound in one segment; it requires a broad-based recovery in volumes across the major businesses that utilize these eleven key shared sites.7 This makes the path to restoring peak profitability more complex and highlights the importance of management’s strategic priority to drive higher sales volumes and enhance utilization rates across the entire manufacturing network.

VI. Growth Strategy & Future Opportunities

Despite the recent cyclical headwinds, Croda’s management has maintained a clear focus on its long-term growth strategy. The strategy is centered on leveraging innovation and sustainability to expand its leadership position in high-value, high-growth market niches.

Innovation Pipeline and R&D Focus

Innovation remains the cornerstone of Croda’s value proposition. The company’s ability to develop novel and patent-protected products is a key differentiator. This is quantitatively measured by the sales contribution from New and Protected Products (NPP). In a strong validation of the R&D engine’s effectiveness, NPP sales grew 6% in constant currency in 2024 and increased to 35% of total Group sales, up from 33% in 2023.7 This demonstrates that even during a market downturn, customers continue to value and adopt Croda’s latest innovations. To sharpen this focus, the R&D teams now report directly into the Consumer Care and Life Sciences business units, ensuring that innovation priorities are directly aligned with customer needs and market opportunities.11

Biotechnology and Sustainable Chemistry

Biotechnology is a core pillar of Croda’s future growth and sustainability strategy. The company is significantly scaling its capabilities in this area, viewing it as a disruptive science that can create a new generation of high-performance, sustainable ingredients.42 This strategy is being executed through a combination of internal development and targeted acquisitions, including Nautilus (marine biotechnology), Enza Biotech (enzymes), and most recently Solus Biotech (bio-derived ceramides and phospholipids).24

A key strategic initiative is the use of biotechnology to replace traditional petrochemical feedstocks. For example, at its Atlas Point facility in the US, Croda has invested in the capacity to use bio-ethanol derived from biomass to produce bio-based ethylene oxide. This is a critical building block for its ECO range of 100% renewable surfactants, which allows customers to significantly improve the sustainability profile of their products without compromising on performance.26 This aligns perfectly with the major industry trend towards green chemistry and provides Croda with a powerful competitive advantage.19

Expansion in High-Growth Niches

Croda’s strategy involves concentrating its resources on market segments with the most attractive long-term growth dynamics.

  • Pharma and Biologics Delivery: The company’s Pharma strategy is to “Empower biologics delivery”.44 The 2020 acquisition of Avanti Polar Lipids established Croda as a world leader in the supply of high-purity lipid systems, which are critical components for mRNA vaccines and next-generation gene therapies.45 Recognizing the immense potential of this market, Croda is making significant capital investments to expand its GMP (Good Manufacturing Practice) production capacity in the US and Europe, positioning itself as a key partner for major pharmaceutical companies developing these advanced therapies.10 The 2023 acquisition of Solus Biotech further strengthens this platform by adding pharmaceutical-grade phospholipids to the portfolio.43
  • Sustainable Agriculture: In its Agriculture business, the growth strategy is focused on providing sustainable solutions that help farmers increase yields while minimizing environmental impact. Key innovation areas include advanced delivery systems that improve the efficacy of both conventional and biological pesticides, and microplastic-free seed coatings that enhance seed performance ahead of new regulations.11

Acquisition Strategy

Croda has a successful track record of using bolt-on M&A to acquire disruptive technologies and accelerate its entry into attractive new markets. The acquisitions made since 2020 have been instrumental in reshaping the portfolio and executing the strategic pivot:

  • Iberchem (2020): Transformed the Consumer Care segment by adding a fast-growing, emerging-market-focused Fragrances & Flavours business.34
  • Avanti Polar Lipids (2020): Provided the foundational technology for the high-growth lipid delivery systems platform in Pharma.34
  • Solus Biotech (2023): Added high-growth, biotechnology-derived ceramides for skincare and hair care, as well as pharmaceutical-grade phospholipids, strengthening both the Consumer Care and Life Sciences businesses.9

The successful integration and performance of these businesses are central to delivering on the company’s long-term growth ambitions.

VII. Capital Allocation & Shareholder Returns

Croda’s capital allocation framework is designed to balance investment for long-term growth with providing consistent and attractive returns to shareholders. The discipline and effectiveness of this framework are critical for long-term value creation.

Historical Capital Deployment Priorities

Management has a clearly defined set of capital allocation priorities. The primary focus is on reinvesting in the business to drive organic growth through capital expenditure (capex) and R&D.8 Following this, the company is committed to providing regular and growing returns to shareholders through a progressive dividend policy. The third priority is to pursue value-accretive, technology-led acquisitions that align with the company’s strategic focus on high-growth niches. Finally, the company aims to maintain an appropriate balance sheet, targeting a leverage ratio of 1-2 times net debt to EBITDA.8

Croda has recently come through a period of “peak investment,” where capex was elevated to fund major growth projects, particularly the expansion of its Pharma manufacturing capacity in the US to support the biologics delivery platform.10 As these projects are commissioned, management has guided that investment intensity and capex are expected to moderate.7 This moderation is already evident, with net capex falling in 2024, and is expected to be a significant driver of improved free cash flow generation in the coming years.39

Dividend Policy and Sustainability

A key component of Croda’s investment case is its exceptional track record of shareholder returns. The company has a 32-year history of progressive, unbroken dividend growth, a testament to the resilience of its business model and management’s commitment to shareholders.40 This record was maintained even through the challenging conditions of 2023 and 2024. For the full year 2024, the Board proposed a dividend of 110.0p per share, a 0.9% increase over the prior year.7 This decision, made despite a decline in earnings, signals the Board’s confidence in the future cash-generating capacity of the business. The sustainability of the dividend is supported by the company’s strong balance sheet and the expected improvement in free cash flow as capex moderates.

Discipline and Returns on Invested Capital

The ultimate measure of capital allocation effectiveness is the return generated on invested capital (ROIC). As noted previously, Croda’s ROIC has declined in recent years, falling to 7.1% in 2024, as the earnings contribution from significant recent investments has yet to fully materialize.8 Improving this metric is a key focus for management. The strategic actions to drive sales growth, increase asset utilization, and control costs are all aimed at growing earnings and improving returns on the capital that has been deployed. The successful integration of acquisitions like Solus Biotech, where sales of acquired ceramides were up approximately 50% in the first half of 2025, will be critical to demonstrating the value of this investment and driving an improvement in overall group ROIC.41

VIII. Management Quality & Corporate Governance

The quality and experience of a company’s leadership team are crucial determinants of its ability to execute strategy and create long-term shareholder value. Croda is led by an experienced management team and governed by a board with a diverse set of relevant skills.

Leadership Assessment

Steve Foots, Group Chief Executive: Mr. Foots has been CEO since the beginning of 2012 and has an exceptionally long tenure with the company, having joined as a graduate trainee in 1990.46 This provides him with unparalleled institutional knowledge and a deep understanding of the company’s markets, technologies, and culture. He has been the primary architect of the company’s strategic transformation, overseeing the divestment of lower-margin industrial assets and the strategic acquisitions that have refocused the portfolio on Life Sciences and Consumer Care. His leadership during the recent downturn has been characterized by a dual focus on immediate cost control and continued investment in long-term strategic priorities. His contribution to the industry was recognized with the award of a Commander of the Order of the British Empire (CBE) in 2025.47

The broader executive committee includes leaders with deep experience within Croda and the wider chemical and pharmaceutical industries, such as Sandra Breene (President, Consumer Care) and the more recent appointment of Thomas Riermeier (President, Life Sciences), who previously led the Health Care business at competitor Evonik.47

Board Oversight and Governance Standards

As a FTSE 100 company, Croda adheres to the UK Corporate Governance Code.2 The Board of Directors is responsible for overall leadership, strategy, and risk oversight.50 The Board has seen recent refreshment at its most senior level, with Danuta Gray appointed as Chair in April 2024, succeeding Dame Anita Frew.51 Ms. Gray brings extensive board experience from a range of FTSE-listed companies, including Direct Line Group and Burberry.51 The Board also includes non-executive directors with relevant experience in consumer markets, finance, and international business, such as Ian Bull, who was appointed in June 2024 and serves as Audit Committee Chair at Dunelm Group.52

The Board has established standard committees to oversee key areas of governance, including Audit, Nomination, Remuneration, and a Sustainability Oversight Committee, which underscores the strategic importance of sustainability to the company.50

Management Communication and Incentive Alignment

Analysis of management’s communication through earnings calls and investor presentations indicates a generally transparent approach.10 During the recent downturn, management was candid about the challenges of destocking, low visibility, and margin pressures, while consistently reinforcing the long-term strategic rationale for their actions. Remuneration policies are designed to align management incentives with shareholder value creation, incorporating both financial and non-financial metrics, including sustainability targets.8

IX. Valuation Analysis

Croda’s valuation has undergone a significant transformation over the past five years. After reaching peak multiples in 2021 on the back of record earnings and market optimism, the stock has de-rated substantially as its financial performance has been impacted by cyclical headwinds. This section analyzes the company’s current valuation in the context of its historical trading ranges and its specialty chemical peers.

Historical Multiple Analysis

Croda has historically traded at a premium valuation relative to the broader chemicals sector, a reflection of its superior growth profile, high-profit margins, and strong returns on capital. However, the downturn of 2023-2024 has led to a significant compression of its valuation multiples.

  • Price-to-Earnings (P/E) Ratio: At its peak in December 2021, Croda’s LTM P/E ratio reached 49.4x. This fell dramatically to a 5-year low of 13.5x by the end of 2022 as the market began to anticipate the earnings decline. At the end of 2024, the P/E ratio stood at 25.3x.53 The forward P/E ratio based on 2025 earnings estimates is approximately 17.3x, which is significantly below its ten-year average forward P/E of 25.3.39
  • Enterprise Value to EBITDA (EV/EBITDA) Ratio: This multiple, which is independent of capital structure, tells a similar story. The LTM EV/EBITDA multiple peaked at 31.4x in December 2021 before falling to 17.6x at the end of 2022. At the end of 2024, the multiple stood at 15.6x.55 The current LTM multiple is approximately 10-11x, which is also well below its historical average.55

This de-rating suggests that the market has repriced the stock to reflect the recent earnings decline and near-term uncertainty. The core valuation question is whether these multiples represent a new, lower normal for the company, or an attractive entry point if Croda can successfully execute its strategy and return to its historical growth and profitability trajectory.

Peer Group Valuation Comparison

Benchmarking Croda against its direct peers provides additional context, although direct comparisons are imperfect due to differences in business mix and geographic exposure. As shown in Table 3, Croda’s valuation multiples are broadly in line with or at a slight premium to some of its major European peers, but the premium it once commanded has narrowed considerably.

Table 3: Valuation Multiples – Historical and Peer Comparison

MetricCroda (CRDA)DSM-Firmenich (DSFIR)Evonik (EVK)
P/E Ratio (LTM)~25.3x~9.6x – 517x (Varies widely by source)~13.6x – 31.2x (Varies by source)
P/E Ratio (Forward)~17.3xNot AvailableNot Available
EV/EBITDA (LTM)~11.0x~10.4x~5.3x – 6.8x
Croda 5-Year Avg. P/E (LTM)~34.2xN/A~9.5x
Croda 5-Year Avg. EV/EBITDA (LTM)~22.3xN/A~6.7x
Sources: Finbox, companiesmarketcap.com, multiples.vc. Data as of late 2024/early 2025. Peer data can be inconsistent across sources due to reporting standards and recent corporate actions (e.g., DSM-Firmenich merger). 28

The data suggests that while Croda is no longer trading at the significant premium it held in 2021, it is not valued at a material discount to its peer group. Its valuation appears to reflect a balance between its high-quality business model and the recent earnings headwinds.

Sum-of-the-Parts (SOTP) Considerations

A qualitative sum-of-the-parts analysis suggests that there may be hidden value within Croda’s portfolio. The Life Sciences segment, particularly the Pharma business with its exposure to the high-growth biologics and mRNA delivery markets, could arguably command a much higher valuation multiple than a traditional specialty chemicals business. As this segment grows and its earnings stream becomes more significant and visible to the market, it could act as a catalyst for a re-rating of the entire company. Similarly, the high-margin, IP-rich Beauty Actives business could also be valued at a premium. This portfolio of distinct, high-quality businesses may not be fully appreciated by a single consolidated valuation multiple.

X. Key Risks & Considerations

A thorough investment analysis requires a clear-eyed assessment of the potential risks to the business and its financial performance. For Croda, these risks span economic, operational, regulatory, and strategic domains.

  • Economic and Cyclical Exposure: The 2023 downturn was a stark reminder that despite its specialty focus, Croda is not immune to macroeconomic cycles. Its Consumer Care segment is exposed to shifts in discretionary consumer spending, particularly in prestige beauty categories. The Crop Protection and Industrial Specialties businesses are linked to the broader agricultural and industrial economic cycles. A weaker-than-expected global economic environment could slow the pace of the demand recovery.39
  • Raw Material Volatility and Pricing Power: Croda’s profitability is sensitive to the price of its raw materials, a significant portion of which are bio-based and subject to agricultural commodity price fluctuations. While the company has historically demonstrated strong pricing power to pass on cost increases, a rapid and unexpected spike in input costs could temporarily compress margins before price adjustments can be implemented.35 Conversely, falling raw material prices can create a price/mix headwind, as seen in 2024.10
  • Operational Gearing and Margin Risk: As highlighted by the 2023 performance, Croda’s integrated manufacturing network, with its eleven key shared production sites, creates significant negative operating leverage during periods of low volume. A slower-than-anticipated recovery in volumes across multiple segments could delay the restoration of profit margins to historical levels, as the burden of under-absorbed fixed costs would persist.
  • Regulatory Risks: The company operates in highly regulated end-markets. In Pharma, its ingredients must meet stringent quality and safety standards set by global health authorities. In Agriculture, its products are subject to environmental regulations, such as those governing pesticides. Unforeseen changes in these regulations could necessitate costly product reformulations or manufacturing process changes. While Croda has shown an ability to turn regulation into an opportunity (e.g., microplastics), this remains a persistent risk.8
  • Acquisition and Integration Risks: Croda’s strategy relies on targeted M&A to acquire new technologies and market access. There is an inherent risk that acquisitions may not be integrated successfully or that the expected synergies and financial returns may not be fully realized. The performance of recent large acquisitions like Iberchem, Avanti, and Solus Biotech will be a key test of management’s M&A capabilities.
  • Technology Disruption and Competition: Croda’s competitive advantage is built on technological leadership in its chosen niches. There is a constant risk that a competitor, including large, well-funded peers like DSM-Firmenich or BASF, could develop a superior or more cost-effective technology, eroding Croda’s market position.

XI. Concluding Remarks: A Balanced Outlook

Croda International PLC presents a compelling case study of a high-quality, innovation-led company at a cyclical crossroads. The analysis reveals a business with a fundamentally strong and defensible model that has been significantly tested by a severe, industry-wide downturn. The investment outlook over a 3-5 year horizon hinges on the interplay between its enduring strategic strengths and its ability to overcome near-term challenges.

The bull case for Croda is anchored in the successful execution of its strategic pivot. By focusing on the high-growth, knowledge-intensive markets of Life Sciences and Consumer Care, the company is aligning itself with powerful long-term trends in biologics, wellness, and sustainability. Its innovation engine continues to deliver, with a growing portfolio of New and Protected Products that command premium pricing. Leadership in biotechnology and sustainable chemistry provides a durable competitive advantage in an industry where these attributes are increasingly valued by customers and mandated by regulators. For an investor with a long-term perspective, the significant de-rating of the company’s valuation multiples from their 2021 peaks could represent an attractive opportunity to invest in a superior business model at a more reasonable price.

The bear case, however, cautions against underestimating the near-term headwinds. The pace of recovery in key markets, particularly Crop Protection, remains uncertain. The 2023 downturn exposed a margin vulnerability linked to the company’s shared asset base, suggesting that a return to peak profitability may be a slower and more arduous process than anticipated. Increased competition from newly scaled players like DSM-Firmenich and the persistent threat of a global economic slowdown pose further risks to the recovery thesis. A failure to deliver on earnings growth could lead to a structural de-rating, where the stock no longer commands the premium valuation it has historically enjoyed.

In conclusion, while no formal recommendation is provided, the balance of evidence suggests a favorable long-term outlook for Croda, contingent on management’s ability to execute its clearly articulated strategy. The company’s financial position is strong, its strategic direction is sound, and its core competitive advantages remain intact. The key signposts for investors to monitor will be the trajectory of volume growth and margin recovery in the Life Sciences and Consumer Care segments, the continued commercial success of the NPP pipeline, and the tangible delivery of the announced operational efficiency and cost-saving programs. Successful execution on these fronts should enable Croda to navigate the remaining cyclical challenges and deliver on the significant growth potential of its refocused, high-value portfolio.

Frequently Asked Questions

Earnings, Business Model, and Market Position

  • Are earnings at a cyclical high or cyclical low? Earnings are at a cyclical low but appear to be in a recovery phase. After reaching a record peak in 2022, profits declined significantly in 2023 due to a widespread industry destocking cycle and weaker macroeconomic conditions. 2024 was described by management as a “transitional year” where profits stabilized at this lower level, in line with revised expectations. Performance in the first half of 2025 showed good sales growth, suggesting the business is moving off the cyclical bottom.  
  • Are earnings driven primarily by the external environment (commodity producer), or internal company actions? Recent earnings volatility has been driven primarily by the external environment. The sharp decline in 2023 was a direct result of global customer destocking and a weak macro environment, not a change in the company’s operations. However, Croda is not a commodity producer; it is a specialty chemicals company whose underlying profitability is driven by internal actions. Its long-term value is derived from its innovation pipeline (New and Protected Products), strategic focus on high-value niches, and deep customer relationships—all factors controlled by the company.  
  • Can this business be easily understood? Yes, the fundamental business model is straightforward and can be understood. Croda develops and sells high-performance specialty ingredients that are critical to the function of a customer’s end product (like a skincare cream or a vaccine) but make up only a small fraction of that product’s total cost. This “high-value, low-inclusion” model allows Croda to build strong partnerships and command premium prices based on performance and innovation rather than volume. The company operates through three clear segments: Consumer Care, Life Sciences, and Industrial Specialties.  
  • Can this company be undermined by foreign, low-cost labor? This is unlikely. Croda’s competitive advantage is built on knowledge-intensive factors such as scientific innovation, a large R&D team, intellectual property, deep technical collaboration with customers, and navigating complex regulatory environments. These create high barriers to entry that cannot be easily replicated by competitors relying on low-cost labor.  
  • Do brands matter in the business? Or is this a commodity producer? Croda is a specialty producer, not a commodity business. In this context, its corporate brand and reputation are critical. Customers, which are other businesses, rely on Croda’s brand as a mark of quality, innovation, reliability, and sustainability leadership. This trust is essential for securing long-term partnerships, particularly in highly regulated markets like pharmaceuticals and high-performance consumer products.  
  • Does the company have assets that are not fully recognized in the balance sheet? Yes, like many knowledge-based companies, Croda’s most valuable assets are likely its intangible ones, which are not fully captured on the balance sheet. These include the value of its internally generated intellectual property (a portfolio of over 1,700 patents), its deep, collaborative customer relationships which create high switching costs, and its extensive regulatory expertise. The consistent growth in sales from New and Protected Products (NPP) is a strong indicator of this off-balance-sheet value.  

Corporate Actions and Governance

  • Does the company issue large amounts of new shares to insiders? There is no evidence of the company issuing unusually large amounts of new shares to insiders. Executive remuneration includes long-term incentive plans where a portion of compensation is delivered in shares, which is a standard practice to align management with shareholder interests. The company also has a “Free Share Plan” for its broader employee base, linking their rewards to the company’s success. Shareholder approval is sought for share allotment authority at the Annual General Meeting (AGM), but this is a standard governance procedure and does not reflect actual issuance.  
  • Has the business environment changed recently? Yes, the business environment has been highly volatile. Following record demand and supply chain disruption in 2021-2022, the industry faced a severe destocking cycle and weak demand in 2023. The environment in 2024 and 2025 has been one of stabilization and early recovery, though management notes that the unpredictable economic and political environment continues to create uncertainty. A significant long-term trend is the accelerating demand for sustainable and bio-based ingredients, which directly benefits Croda’s strategic focus.  
  • Has the company made any significant acquisitions recently? Yes. Croda has made several strategically important acquisitions to refocus its portfolio on higher-growth markets. Key recent transactions include:
    • Solus Biotech (2023): A leader in biotechnology-derived ceramides and phospholipids, strengthening both the Beauty Actives and Pharma businesses.  
    • Avanti Polar Lipids (2020): Established Croda as a leader in lipid systems for drug delivery, crucial for mRNA and gene therapy applications.  
    • Iberchem (2020): Added a fast-growing fragrances and flavors business with a strong emerging market footprint.  
  • Has the company recently changed accounting policies? Yes, the company adopted new accounting policies on January 1, 2024, to comply with amendments to international standards (IFRS). However, these changes did not have a material impact on the Group’s financial reporting.  

Financial Health and Capital Allocation

  • How CapEx hungry is this business? What % of cash from operations must be spent on CapEx to sustain the business? Croda has recently completed a period of “peak investment” to build new capacity, particularly in its Pharma business. Management’s stated policy is to invest 6-8% of sales in capital expenditure annually to maintain and grow the business, with an expectation that this will trend toward the lower end of the range as new projects are completed. While the company does not split out maintenance versus growth capex, the recent major investments in new facilities are clearly for growth. The moderation of this growth-focused spending is expected to be a key driver of higher free cash flow in the coming years.  
  • How conservative is the company’s accounting? Are they over- or under- stating earnings? The company’s accounting appears to be conventional and transparent for a UK-listed public company. It reports under IFRS and provides reconciliations for “adjusted” performance measures, which exclude exceptional items to give a clearer view of underlying business performance. This is standard practice and there is no indication of any attempt to artificially over- or under-state earnings.  
  • How many options / shares is the management issuing to insiders? Is it more than 10% of net income? The value of shares issued to insiders under long-term incentive plans is a small fraction of net income. For example, the CEO’s total pay in 2023 was approximately £1.34 million, whereas the company’s adjusted profit before tax was £308.8 million. This is well below the 10% threshold.  
  • How much free cash flow does the business generate? How does management use this free cash flow? What is their philosophy? Croda has demonstrated resilient cash generation. Free cash flow was £181.1 million in 2024, an increase from £165.5 million in 2023 and £157.4 million in 2022. Management’s capital allocation philosophy is clear and disciplined: the first priority is reinvesting for organic growth (capex and R&D), followed by a commitment to a progressive dividend. After these priorities are met, capital is used for strategic acquisitions, with any excess capital returned to shareholders while maintaining a target leverage of 1-2x net debt to EBITDA.  
  • How profitable is this business? What is the return on capital invested? Return on equity? Croda is a highly profitable business, though margins have been impacted by the recent cyclical downturn.
    • Profitability: The adjusted operating margin was 17.2% in 2024, down from its recent peak of 24.7% in 2022.  
    • Return on Invested Capital (ROIC): ROIC was 7.1% in 2024, down from 14.1% in 2022, reflecting lower profits and a higher capital base from recent investments. Management has made improving ROIC a key priority.  
    • Return on Equity (ROE): Recent normalized ROE has been reported in the range of 6-9%.  
  • Is net income diverging from cash from operations? Yes, in the recent downturn, cash flow has been stronger than income. In both 2023 and 2024, adjusted profits declined, but free cash flow increased each year. This divergence was driven by disciplined working capital management, particularly reducing inventory levels, which generated a cash inflow and demonstrated strong operational control during a challenging period.  
  • Is the company buying back shares? Paying dividends? The company has a strong commitment to its dividend, with a 32-year track record of not reducing it. The dividend was increased for 2024. While the company has shareholder authorization to buy back shares, it is not a stated priority in its capital allocation framework, and there is no active buyback program currently mentioned. The focus for shareholder returns is the progressive dividend.  

Industry and Market Outlook

  • How profitable is this industry? Are there a lot of competitors? What are the barriers to entry? The specialty chemicals industry is structurally profitable due to the high-performance, application-specific nature of its products. There are many competitors, including large, well-funded companies like DSM-Firmenich, Evonik, and BASF, as well as smaller niche players. Barriers to entry are high and include the need for significant R&D investment, deep technical expertise, established customer relationships with high switching costs, and sophisticated regulatory knowledge.  
  • How stable are revenues? How much do they fluctuate with the economy? Revenues are cyclical and fluctuate with the broader economy and levels of consumer spending. This was clearly demonstrated by the sharp sales decline from £2.09 billion in 2022 to £1.69 billion in 2023 during the industry-wide destocking event. While the company’s focus on specialty niches provides some insulation compared to commodity chemicals, it is not immune to significant macroeconomic shifts.  
  • Outlook for the company’s products and services? How big will this market be? Is it growing? Shrinking? Domestic or international? The outlook is positive. Croda operates in the global specialty chemicals market, which is a large, international market valued at over $640 billion and projected to grow at a compound annual rate of 4-5% to reach approximately $1 trillion by 2030. Growth is driven by megatrends such as sustainability, demand for bio-based ingredients, and innovation in end-markets like pharmaceuticals, electronics, and personal care, all of which align with Croda’s strategic focus.  
  • Recent changes in the business, new markets, new production facilities, what’s changed recently? New management? The business has undergone significant recent changes:
    • Strategic: Completed its pivot to focus on Consumer Care and Life Sciences following the 2022 divestment of most of its industrial business.  
    • Facilities: Opened a new advanced lipids facility in Pennsylvania in March 2025 and made an Argentinian seed enhancement site fully operational in August 2025. New plants are also under construction in India and China.  
    • Management: There has been recent refreshment in key leadership roles. Danuta Gray was appointed Chair in April 2024, Stephen Oxley became CFO in April 2025, and Thomas Riermeier became President of Life Sciences in April 2025.  

Risk and Investment Considerations

  • What are the motivations of management? Do they own a lot of stock and options? Management’s motivation is strongly aligned with long-term shareholder value. The remuneration structure is heavily weighted towards variable pay tied to performance metrics including profit growth, total shareholder return (TSR), and key strategic goals like innovation and sustainability. Furthermore, executives are required to build and maintain a significant personal shareholding in the company, equivalent to 200-250% of their base salary, ensuring they have a vested interest in its success.  
  • What are the recent news on the company? Key news since August 2025 includes:
    • Product Innovation: The launch of Zenakine™, a new biotech-derived skincare ingredient (September 2025).  
    • Operational Expansion: An upgraded seed enhancement facility in Argentina became fully operational (August 2025).  
    • Financial Results: The company reported its half-year 2025 results, showing good sales growth and an increased cost-saving target (July 2025).  
  • What factors would cause the stock to decline? Are these factors controlled by the company or the external environment? Factors that could cause the stock to decline include:
    • External (Uncontrollable): A renewed global economic slowdown, a reversal in the recovery of consumer spending, or another sharp destocking cycle in the chemical industry.  
    • Internal (Company-Controlled): A failure to restore profit margins, an inability to deliver expected returns from recent large investments, a slowdown in the innovation pipeline, or poor integration of recent acquisitions.  
  • What is the nature of competition? Do brand names matter? What are the customers switching costs? Competition comes from large, global specialty chemical companies. Croda’s brand reputation is a key competitive advantage, signifying innovation and quality to its business customers. Customer switching costs are very high, which is a cornerstone of Croda’s business model. These costs are created by embedding its highly specialized ingredients into customer formulations through collaborative R&D, making it difficult and expensive for a customer to reformulate their product with a competitor’s ingredient.  
  • What is the risk of a catastrophic loss on this investment? What is the chance of a total loss? The risk of a total loss on an investment in Croda is extremely low. It is a well-established, profitable FTSE 100 company with a strong balance sheet, a diversified global business, and a long history of dividend payments. While the stock price is subject to market and cyclical risks, the company’s financial stability and market position make the possibility of insolvency remote.  
  • What off B/S liabilities does the company have? The annual report does not highlight any significant or unusual off-balance sheet liabilities. The company reports under IFRS, which requires most lease obligations to be capitalized on the balance sheet. While environmental provisions are noted, they are accounted for on the balance sheet.  
  • What is the compensation policy of directors and management? The compensation policy is designed to align executive pay with long-term, sustainable shareholder value. It comprises a mix of fixed salary, an annual bonus tied to profit and ESG targets, and a long-term incentive plan (Performance Share Plan) that vests based on multi-year performance in earnings per share, total shareholder return, and strategic innovation and sustainability goals.  
  • Is the stock an ADR? What are the ADR fees? Yes, in addition to its primary listing on the London Stock Exchange (CRDA.L), Croda has an American Depositary Receipt (ADR) which trades on the US over-the-counter (OTC) market under the ticker COIHY. It is an “unsponsored” ADR, meaning multiple depositary banks can issue it. Holders of the ADR are typically subject to an annual depositary service fee, which for UK stocks is often in the range of $0.02 per share, in addition to other potential transaction fees.  

Sources and related content 

Works cited

  1. Croda Home | Croda, accessed September 14, 2025, https://www.croda.com/en-gb
  2. Croda crowned Britain’s Most Admired Chemicals Company for eighth year running, accessed September 14, 2025, https://www.croda.com/en-gb/media-hub/news/general/croda-crowned-most-admired-chemicals-company-for-eighth-year-running
  3. Investors | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/investors
  4. Results, presentations and reports – Croda, accessed September 14, 2025, https://www.croda.com/en-gb/investors/results-presentations-and-reports
  5. Croda 2022 Sustainability Report, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/reporting-2022/croda-sustainability-report-2022.pdf?la=en-GB&hash=8ADB729A7E039289ECB38350707AC503
  6. Croda International PLC (CRDA) – Morningstar, accessed September 14, 2025, https://www.morningstar.com/stocks/xlon/crda/quote
  7. Full year results announcement 2024 | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/media-hub/news/general/full-year-results-announcement-2024
  8. 2024 Reporting – Croda, accessed September 14, 2025, https://www.croda.com/en-gb/investors/annual-reporting
  9. Investor overview | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/investors/investor-overview
  10. Croda International Plc Results for the 12 months ended 31 …, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/investors/2024-full-year-results/croda-international-fy24-results-call-transcript.pdf?la=en-GB&hash=F6ED8C106699CF7E95065C563A0625AF
  11. Our strategy – Croda, accessed September 14, 2025, https://www.croda.com/en-gb/about-us/our-strategy
  12. Smart Science to Improve LivesTM – Croda, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/investors/annual-reports/2019-croda-annual-report.pdf?la=en-GB&hash=E8A2C32F8752D5474251B000777864D7
  13. 29 July 2025 Results for the six months ended 30 June 2025 Good sales growth with FY25 outlook unchanged; delivering on our plan to grow earnings and improve returns – Croda, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/investors/half-year-2025/croda-h1-2025-results-statement-final-29-july-2025.pdf?la=en-GB&hash=78690B536A9A4DFC5E8B451F2353BBC0
  14. Specialty Chemicals Market Size, Share | CAGR of 4.9%, accessed September 14, 2025, https://market.us/report/specialty-chemicals-market/
  15. Specialty Chemicals Market, Industry Size Forecast [Latest] – MarketsandMarkets, accessed September 14, 2025, https://www.marketsandmarkets.com/Market-Reports/global-specialty-chemicals-165.html
  16. Specialty Chemicals Market Size & Share Report, 2030 – Grand View Research, accessed September 14, 2025, https://www.grandviewresearch.com/industry-analysis/specialty-chemicals-market
  17. Specialty Chemicals Market Size, Share, Forecast to 2033 – Straits Research, accessed September 14, 2025, https://straitsresearch.com/report/specialty-chemicals-market
  18. The Booming Specialty Chemicals Market: Trends, Opportunities, and Challenges, accessed September 14, 2025, https://blog.bccresearch.com/the-booming-specialty-chemicals-market-trends-opportunities-and-challenges
  19. The Future of Specialty Chemicals: Key Trends and Innovations Shaping the Industry, accessed September 14, 2025, https://www.knowledge-sourcing.com/resources/blogs/the-future-of-specialty-chemicals-key-trends-and-innovations/
  20. 4 trends shaping the chemicals industry landscape in 2025 – Elsevier, accessed September 14, 2025, https://www.elsevier.com/industry/4-key-chemicals-industry-trends
  21. Specialty Chemicals Market Size, Share, Growth & Trends Report [2031] – Kings Research, accessed September 14, 2025, https://www.kingsresearch.com/specialty-chemicals-market-591
  22. 2025 Chemical Industry Outlook | Deloitte Insights, accessed September 14, 2025, https://www.deloitte.com/us/en/insights/industry/chemicals-and-specialty-materials/chemical-industry-outlook.html
  23. Specialty Gaines: Q3 Key Industry Trends in the U.S. Specialty Chemicals Industry – SOCMA, accessed September 14, 2025, https://www.socma.org/specialty-gaines-q3-key-industry-trends-in-the-u-s-specialty-chemicals-industry/
  24. Innovation – Croda, accessed September 14, 2025, https://www.croda.com/en-gb/smart-science/innovation
  25. croda-2021-annual-report.pdf, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/reporting-2021/croda-2021-annual-report.pdf?la=en-GB&hash=96CF03D24B88EB7BCF3B4E7F1BC9837F
  26. ECO range | Croda Industrial Specialties, accessed September 14, 2025, https://www.crodaindustrialspecialties.com/en-gb/sustainability/eco-range
  27. Croda International Plc Third quarter trading update conference call …, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/investor-result-downloads/2023/croda-international-plc-third-quarter-trading-update-call-transcript.pdf?la=en-GB&hash=CA65F04DD9D144E79535C60DD4B674B7
  28. DSM Firmenich – Public Comps and Valuation Multiples, accessed September 14, 2025, https://multiples.vc/public-comps/dsm-firmenich-valuation-multiples
  29. Croda International Plc Overview – Company Profile – GlobalData, accessed September 14, 2025, https://www.globaldata.com/company-profile/croda-international-plc/
  30. Croda International Plc Peers & Key Competitors – GlobalData, accessed September 14, 2025, https://www.globaldata.com/company-profile/croda-international-plc/competitors/
  31. Annual Report 2022 | DSM-Firmenich, accessed September 14, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/merger-documents/financial-information-referenced-in-the-offering-circular/firmenich-annual-report-for-the-financial-year-ended-2022.pdf
  32. ESG Investments – BASF, accessed September 14, 2025, https://www.basf.com/global/en/investors/sustainable-investments
  33. Full year 2021 results – Croda, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/investor-result-downloads/2022/croda-fy21-results-presentation-1-march-2022-final.pdf?la=en-GB&hash=8742BB818E581AE299103AB1D9916DE5
  34. Croda International Plc Results for the year ended 31 December 2021 Call transcript, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/investors/croda-international-fy-2021-results-transcript.pdf?la=en-GB&hash=11ED5A34790521FF09821DE60350DC5F
  35. Croda International Plc Results for the year ended 31 December …, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/investors/croda-international-plc-2022-full-year-results-call-transcript.pdf?la=en-GB&hash=CC9C5DEBDA0D8984B0F37AEEEB944F13
  36. Annual Report archive | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/investors/annual-reporting/annual-report-archive
  37. Results for the year ended 31 December 2023 – 07:00:08 26 Feb 2024 – CRDA News article | London Stock Exchange, accessed September 14, 2025, https://www.londonstockexchange.com/news-article/CRDA/results-for-the-year-ended-31-december-2023/16349817
  38. Croda FY24 results, accessed September 14, 2025, https://www.croda.com/mediaassets/files/corporate/investors/2024-full-year-results/croda-fy24-results-analyst-presentation-25-feb-2025.pdf?la=en-GB&hash=D1B3C55CF98E5C212B43522F39331A4F
  39. Croda International: strategic progress in a challenging 2024 | HL – Hargreaves Lansdown, accessed September 14, 2025, https://www.hl.co.uk/shares/share-research/croda-international-strategic-progress-in-a-challenging-2024
  40. Full year results announcement 2023 | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/media-hub/news/general/full-year-results-announcement-2023
  41. Half year results announcement 2025 | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/media-hub/news/general/half-year-2025-results
  42. Biotechnology at Croda, accessed September 14, 2025, https://www.croda.com/en-gb/smart-science/biotechnology-at-croda
  43. Acquisition of Solus Biotech expands specialised Pharma business in Asia, accessed September 14, 2025, https://www.crodapharma.com/es-mx/news-and-blog/solus-acquisition-press-release
  44. New Pharma business | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/media-hub/news/acquisitions-and-partners/new-pharma-business
  45. Investing in mRNA and gene therapy – Croda, accessed September 14, 2025, https://www.croda.com/en-gb/about-us/case-studies/investing-in-mrna-and-gene-therapy
  46. Members of the CGP Innovation Group, accessed September 14, 2025, https://www.soci.org/-/media/Files/Innovation-Group/Steve-Foots.ashx?la=en
  47. Leadership | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/about-us/leadership
  48. Steve Foots – Wikipedia, accessed September 14, 2025, https://en.wikipedia.org/wiki/Steve_Foots
  49. Croda International – Wikipedia, accessed September 14, 2025, https://en.wikipedia.org/wiki/Croda_International
  50. Governance | Croda, accessed September 14, 2025, https://www.croda.com/en-gb/about-us/governance
  51. Appointment of Chair Designate – Croda, accessed September 14, 2025, https://www.croda.com/en-gb/media-hub/news/appointments/appointment-of-chair-designate
  52. Appointment of Non-Executive Director – Croda, accessed September 14, 2025, https://www.croda.com/en-gb/media-hub/news/appointments/appointment-of-non-executive-director-board-succession-planning
  53. Croda International PLC (LSE:CRDA) P/E Ratio – Investing.com, accessed September 14, 2025, https://ng.investing.com/pro/LSE:CRDA/explorer/pe_ltm
  54. P/E Ratio (Fwd) For Croda International PLC (CRDA) – Finbox, accessed September 14, 2025, https://finbox.com/LSE:CRDA/explorer/pe_fwd/
  55. EV / EBITDA For Croda International PLC (CRDA) – Finbox, accessed September 14, 2025, https://finbox.com/LSE:CRDA/explorer/ev_to_ebitda_ltm/
  56. Croda International – Public Comps and Valuation Multiples, accessed September 14, 2025, https://multiples.vc/public-comps/croda-international-valuation-multiples
  57. P/E ratio for DSM-Firmenich (DSFIR.AS) – Companies Market Cap, accessed September 14, 2025, https://companiesmarketcap.com/eur/dsm-firmenich/pe-ratio/
  58. DSM-Firmenich AG (DSFIR.AS) Price-to-Earnings (P/E) Ratio – MLQ.ai | Stocks, accessed September 14, 2025, https://mlq.ai/stocks/DSFIR.AS/pe-ratio/
  59. Evonik Industries (EVK.DE) – P/E ratio – Companies Market Cap, accessed September 14, 2025, https://companiesmarketcap.com/evonik-industries/pe-ratio/
  60. P/E Ratio For Evonik Industries AG (EVK) – Finbox, accessed September 14, 2025, https://finbox.com/WBAG:EVK/explorer/pe_ltm
  61. EV / EBITDA For Evonik Industries AG (EVK) – Finbox, accessed September 14, 2025, https://finbox.com/DB:EVK/explorer/ev_to_ebitda_ltm/
  62. Evonik Industries – Public Comps and Valuation Multiples, accessed September 14, 2025, https://multiples.vc/public-comps/evonik-industries-valuation-multiples